Logo image of CDTX

CIDARA THERAPEUTICS INC (CDTX) Stock Fundamental Analysis

USA - NASDAQ:CDTX - US1717572069 - Common Stock

98.15 USD
-5.07 (-4.91%)
Last: 10/22/2025, 2:33:06 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to CDTX. CDTX was compared to 534 industry peers in the Biotechnology industry. CDTX has a great financial health rating, but its profitability evaluates not so good. CDTX is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CDTX has reported negative net income.
CDTX had a negative operating cash flow in the past year.
In the past 5 years CDTX always reported negative net income.
CDTX had a negative operating cash flow in each of the past 5 years.
CDTX Yearly Net Income VS EBIT VS OCF VS FCFCDTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

With a decent Return On Assets value of -21.99%, CDTX is doing good in the industry, outperforming 75.47% of the companies in the same industry.
CDTX's Return On Equity of -23.44% is amongst the best of the industry. CDTX outperforms 82.21% of its industry peers.
Industry RankSector Rank
ROA -21.99%
ROE -23.44%
ROIC N/A
ROA(3y)-61.33%
ROA(5y)-72.86%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CDTX Yearly ROA, ROE, ROICCDTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K 2K 3K 4K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CDTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CDTX Yearly Profit, Operating, Gross MarginsCDTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

More info and screens

8

2. Health

2.1 Basic Checks

CDTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CDTX has been increased compared to 1 year ago.
Compared to 5 years ago, CDTX has more shares outstanding
Compared to 1 year ago, CDTX has an improved debt to assets ratio.
CDTX Yearly Shares OutstandingCDTX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
CDTX Yearly Total Debt VS Total AssetsCDTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

CDTX has an Altman-Z score of 46.00. This indicates that CDTX is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 46.00, CDTX belongs to the top of the industry, outperforming 95.69% of the companies in the same industry.
There is no outstanding debt for CDTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 46
ROIC/WACCN/A
WACC9.35%
CDTX Yearly LT Debt VS Equity VS FCFCDTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

2.3 Liquidity

CDTX has a Current Ratio of 16.45. This indicates that CDTX is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 16.45, CDTX belongs to the best of the industry, outperforming 91.95% of the companies in the same industry.
A Quick Ratio of 16.45 indicates that CDTX has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 16.45, CDTX belongs to the top of the industry, outperforming 91.95% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 16.45
Quick Ratio 16.45
CDTX Yearly Current Assets VS Current LiabilitesCDTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

4

3. Growth

3.1 Past

CDTX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -77.51%.
Looking at the last year, CDTX shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
Measured over the past years, CDTX shows a very negative growth in Revenue. The Revenue has been decreasing by -42.85% on average per year.
EPS 1Y (TTM)-77.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-18.71%
Revenue 1Y (TTM)-100%
Revenue growth 3Y-70.48%
Revenue growth 5Y-42.85%
Sales Q2Q%-100%

3.2 Future

Based on estimates for the next years, CDTX will show a quite strong growth in Earnings Per Share. The EPS will grow by 16.84% on average per year.
The Revenue is expected to grow by 142.16% on average over the next years. This is a very strong growth
EPS Next Y46.61%
EPS Next 2Y14.17%
EPS Next 3Y10.83%
EPS Next 5Y16.84%
Revenue Next Year-100%
Revenue Next 2Y-19.19%
Revenue Next 3Y-6.54%
Revenue Next 5Y142.16%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CDTX Yearly Revenue VS EstimatesCDTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2019 2020 2021 2022 2023 2024 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
CDTX Yearly EPS VS EstimatesCDTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -50 -100 -150

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CDTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CDTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CDTX Price Earnings VS Forward Price EarningsCDTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CDTX Per share dataCDTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.17%
EPS Next 3Y10.83%

More info and screens

0

5. Dividend

5.1 Amount

CDTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CIDARA THERAPEUTICS INC

NASDAQ:CDTX (10/22/2025, 2:33:06 PM)

98.15

-5.07 (-4.91%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)11-05 2025-11-05
Inst Owners107.01%
Inst Owner Change-0.01%
Ins Owners0.79%
Ins Owner Change0.03%
Market Cap2.49B
Revenue(TTM)N/A
Net Income(TTM)-117490000
Analysts84.62
Price Target134.3 (36.83%)
Short Float %8.73%
Short Ratio3.23
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)36.36%
Min EPS beat(2)18.65%
Max EPS beat(2)54.07%
EPS beat(4)3
Avg EPS beat(4)17.69%
Min EPS beat(4)-45.43%
Max EPS beat(4)54.07%
EPS beat(8)6
Avg EPS beat(8)-97.67%
EPS beat(12)7
Avg EPS beat(12)-52.11%
EPS beat(16)10
Avg EPS beat(16)-34.77%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)77.93%
PT rev (3m)122.54%
EPS NQ rev (1m)-2.55%
EPS NQ rev (3m)31.09%
EPS NY rev (1m)10.8%
EPS NY rev (3m)24.36%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.97
P/tB 4.97
EV/EBITDA N/A
EPS(TTM)-11.13
EYN/A
EPS(NY)-8
Fwd EYN/A
FCF(TTM)-5.09
FCFYN/A
OCF(TTM)-5.09
OCFYN/A
SpS0
BVpS19.76
TBVpS19.76
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -21.99%
ROE -23.44%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-61.33%
ROA(5y)-72.86%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 16.45
Quick Ratio 16.45
Altman-Z 46
F-Score3
WACC9.35%
ROIC/WACCN/A
Cap/Depr(3y)188.62%
Cap/Depr(5y)130.51%
Cap/Sales(3y)3.7%
Cap/Sales(5y)2.54%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-77.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-18.71%
EPS Next Y46.61%
EPS Next 2Y14.17%
EPS Next 3Y10.83%
EPS Next 5Y16.84%
Revenue 1Y (TTM)-100%
Revenue growth 3Y-70.48%
Revenue growth 5Y-42.85%
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y-19.19%
Revenue Next 3Y-6.54%
Revenue Next 5Y142.16%
EBIT growth 1Y-241.09%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year22.14%
EBIT Next 3Y-3.52%
EBIT Next 5YN/A
FCF growth 1Y-9652.72%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-11576%
OCF growth 3YN/A
OCF growth 5YN/A